Ready for some big news? Johnson & Johnson announced they have entered into a definitive agreement to acquire Abbott Medical Optics (AMO) for $4.325 billion in cash. AMO’s business segments include cataract surgery, laser refractive surgery, and consumer eye health, and reported sales in 2015 were $1.1 billion.
It has been a history-making week for the ophthalmic world, and the FDA approval of the first IOL with extended range of vision (Tecnis Symfony IOL, Abbott) has only added one more reason for celebration.
The U.S. IDE clinical trial of the investigational extended range of vision IOL (Model ZXR00; Tecnis Symfony Extended Range of Vision IOL, Abbott Medical Optics) found that the implant delivered a full range of uncorrected vision and minimized or eliminated the need for spectacle wear in most patients.
Ophthalmology Times spoke with its Editorial Advisory Board members to get their thoughts on how the field of ophthalmology is growing, what advances they are highly anticipating, and what major hurdles ophthalmologists will face in 2016. A special thanks to Peter J. McDonnell, MD, Randall Olson, MD, Andrew G. Lee, MD, Sharon Fekrat, MD, and Robert K. Maloney, MD, for giving us a sneak peak at what the new year will bring.
Abbott recently announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for two new products used in laser cataract surgery, the Cataract Operating System 3 (cOS3) and the Liquid Optics Interface 12, both for the company’s Catalys Precision Laser System.